1. Pink Sheet

Prescription Pathways' Friendly Divorce

 
• By Michael McCaughan

The Prescription Pathways joint venture will dissolve at the end of 2008, with CVS Caremark and Universal/MemberHealth divvying up the assets of one of the larger Part D plans. As divorces go, this seems amicable. But what about the children? Or in this case, the elderly and disabled Medicare beneficiaries who may be surprised to learn that they have been transferred to a new plan sponsor.

The Prescription Pathways joint venture will dissolve at the end of 2008, with CVS Caremark and Universal/MemberHealth divvying up the assets of one of the larger Part D plans. As divorces go, this seems amicable. But what about the children?

Prescription Pathways was one of the more innovative business arrangements created to launch Part D, a joint venture of CVS...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 
• By Neena Brizmohun

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 
• By Bridget Silverman

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.